Worth reading
30Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Items stated in the management plan
Net SalesNot disclosed → 5,564 Millions of yen
Operating profitNot disclosed → 438 Millions of yen
Only the target level is shown because the current level for comparison was not provided.Key initiatives
01Increased demand for nucleic acid extraction reagents and consumables
02Planned launch of 2 new ODM products
Plan assumptionsNucleic acid extraction reagents and consumables to grow by approximately 10% annually
Size of the Target MarketA market trend graph for 2020 to 2030 is provided under “Sales value [Million US$].” Nucleic acid extraction reagents and consumables are expected to grow by approximately 10% annually. Source: not disclosed.
| Item | Details |
|---|---|
| Plan name | Medium-term plan |
| Plan period | FY24/6〜FY28/6 |
| Sales Target | Not disclosed → 5,564 Millions of yen |
| Operating profit target | Not disclosed → 438 Millions of yen |
| Plan assumptions | Nucleic acid extraction reagents and consumables to grow by approximately 10% annually |
| Key initiatives | Increased demand for nucleic acid extraction reagents and consumables, Planned launch of 2 new ODM products |
| Size of the Target Market | A market trend graph for 2020 to 2030 is provided under “Sales value [Million US$].” Nucleic acid extraction reagents and consumables are expected to grow by approximately 10% annually. Source: not disclosed. |
Items this document does not state (18)
Progress against the planOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsResults under the previous planReason for revision or withdrawalRisks identifiedDate of board resolutionPublication date
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The stated growth drivers are increased demand for nucleic acid extraction reagents and consumables, annual growth of approximately 10% for these products, and the planned launch of 2 new ODM products.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.